ZYBT
NASDAQ · Pharmaceuticals
Zhengye Biotechnology Holdin
$1.43
+0.05 (+3.62%)
Financial Highlights (FY 2026)
Revenue
69.50M
Net Income
-41,682,877
Gross Margin
20.5%
Profit Margin
-60.0%
Rev Growth
+664.7%
D/E Ratio
0.30
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 20.5% | 66.6% | 66.6% | 66.6% |
| Operating Margin | -60.6% | 21.8% | 23.4% | 26.6% |
| Profit Margin | -60.0% | 22.3% | 18.0% | 17.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 69.50M | 12.11M | 10.68M | 11.04M |
| Gross Profit | 14.26M | 8.07M | 7.12M | 7.36M |
| Operating Income | -42,112,751 | 2.63M | 2.49M | 2.94M |
| Net Income | -41,682,877 | 2.69M | 1.92M | 1.97M |
| Gross Margin | 20.5% | 66.6% | 66.6% | 66.6% |
| Operating Margin | -60.6% | 21.8% | 23.4% | 26.6% |
| Profit Margin | -60.0% | 22.3% | 18.0% | 17.9% |
| Rev Growth | +664.7% | -0.1% | -5.4% | +15.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 4.65M | 9.50M | 11.04M | 9.33M |
| Total Equity | 15.57M | 25.46M | 25.42M | 24.63M |
| D/E Ratio | 0.30 | 0.37 | 0.43 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -26,653,510 | 3.66M | 3.67M | 3.48M |
| Free Cash Flow | — | 1.61M | 1.47M | 1.80M |